All the Active Ingredient Drugs
Monoclonal Antibody. Belimumab 120 mg, 400 mg. VIAL (pwdr. for concentrate for sol. for infus.): 1×120mg.
VIAL (pwdr. for concentrate for sol. for infus.): 1×400mg.
Benlysta 120,400 mg: Premed. includ. an antihistamine, with/without an antipyretic, may be admin. before the infus. The recomm. dose is 10 mg/kg on Days 0, 14 and 28, and at 4-wk. interv. thereafter. The patient’s condition should be evaluated continuous. Discont. of tmt. should be consid. if there is no improve. in dis. control after 6 mnths. of tmt. See lit.
Indic. as add-on ther. in adult pts. with active, autoantibody-posit. system. lupus erythematosus (SLE) with a high degree of dis. activity (e.g., positive anti-dsDNA and low complement) despite standard ther.
C/I: Hypersens.
Monoclonal Antibody. Belimumab 200 mg. PRE-FILL. PEN (sol. for S.C. inj.): 1, 4×200mg/ml.
PRE-FILL.SYR. (sol. for S.C. inj.): 1, 4×200mg/ml.
Benlysta 200mg/ml: 200 mg once wkly., admin. S.C. dosing is not based on weight.
The pt’s. condition should be evaluat. continuous. Discont. of tmt. should be consid. if there is no improv. in dis. control after 6 mnths. of tmt.
If a dose is missed, it should be admin. as soon as possible. Thereafter, pts. can resume dosing on their usual day of admin., or start a new wkly.
Transit. from IV to S.C. admin.: If a pt. is being transitioned from IV admin. to S.C. admin., the 1st S.C. inj. should be admin. 1-4 wks. after the last IV dose. See lit.
Indic. as add-on ther. in adult pts. with active, autoantibody-posit. system. lupus erythematosus (SLE) with a high degree of dis. activity (e.g., positive anti-dsDNA and low complement) despite standard ther.
C/I: Hypersens.
